Impact of serum phosphate changes on in-hospital mortality.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
07 10 2020
Historique:
received: 03 10 2019
accepted: 05 10 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 12 10 2021
Statut: epublish

Résumé

Fluctuations in serum phosphate levels increased mortality in end-stage renal disease patients. However, the impacts of serum phosphate changes in hospitalized patients remain unclear. This study aimed to test the hypothesis that serum phosphate changes during hospitalization were associated with in-hospital mortality. We included all adult hospitalized patients from January 2009 to December 2013 that had at least two serum phosphate measurements during their hospitalization. We categorized in-hospital serum phosphate changes, defined as the absolute difference between the maximum and minimum serum phosphate, into 5 groups: 0-0.6, 0.7-1.3, 1.4-2.0, 2.1-2.7, ≥2.8 mg/dL. Using serum phosphate change group of 0-0.6 mg/dL as the reference group, the adjusted odds ratio of in-hospital mortality for various serum phosphate change groups was obtained by multivariable logistic regression analysis. A total of 28,149 patients were studied. The in-hospital mortality in patients with serum phosphate changes of 0-0.6, 0.7-1.3, 1.4-2.0, 2.1-2.7, ≥2.8 mg/dL was 1.5, 2.0, 3.1, 4.4, and 10.7%, respectively (p < 0.001). When adjusted for confounding factors, larger serum phosphate changes were associated with progressively increased in-hospital mortality with odds ratios of 1.35 (95% 1.04-1.74) in 0.7-1.3 mg/dL, 1.98 (95% CI 1.53-2.55) in 1.4-2.0 mg/dL, 2.68 (95% CI 2.07-3.48) in 2.1-2.7 mg/dL, and 5.04 (95% CI 3.94-6.45) in ≥2.8 mg/dL compared to serum phosphate change group of 0-0.6 mg/dL. A similar result was noted when we further adjusted for either the admission or mean serum phosphate during hospitalization. Greater serum phosphate changes were progressively associated with increased in-hospital mortality.

Sections du résumé

BACKGROUND
Fluctuations in serum phosphate levels increased mortality in end-stage renal disease patients. However, the impacts of serum phosphate changes in hospitalized patients remain unclear. This study aimed to test the hypothesis that serum phosphate changes during hospitalization were associated with in-hospital mortality.
METHODS
We included all adult hospitalized patients from January 2009 to December 2013 that had at least two serum phosphate measurements during their hospitalization. We categorized in-hospital serum phosphate changes, defined as the absolute difference between the maximum and minimum serum phosphate, into 5 groups: 0-0.6, 0.7-1.3, 1.4-2.0, 2.1-2.7, ≥2.8 mg/dL. Using serum phosphate change group of 0-0.6 mg/dL as the reference group, the adjusted odds ratio of in-hospital mortality for various serum phosphate change groups was obtained by multivariable logistic regression analysis.
RESULTS
A total of 28,149 patients were studied. The in-hospital mortality in patients with serum phosphate changes of 0-0.6, 0.7-1.3, 1.4-2.0, 2.1-2.7, ≥2.8 mg/dL was 1.5, 2.0, 3.1, 4.4, and 10.7%, respectively (p < 0.001). When adjusted for confounding factors, larger serum phosphate changes were associated with progressively increased in-hospital mortality with odds ratios of 1.35 (95% 1.04-1.74) in 0.7-1.3 mg/dL, 1.98 (95% CI 1.53-2.55) in 1.4-2.0 mg/dL, 2.68 (95% CI 2.07-3.48) in 2.1-2.7 mg/dL, and 5.04 (95% CI 3.94-6.45) in ≥2.8 mg/dL compared to serum phosphate change group of 0-0.6 mg/dL. A similar result was noted when we further adjusted for either the admission or mean serum phosphate during hospitalization.
CONCLUSION
Greater serum phosphate changes were progressively associated with increased in-hospital mortality.

Identifiants

pubmed: 33028266
doi: 10.1186/s12882-020-02090-3
pii: 10.1186/s12882-020-02090-3
pmc: PMC7542949
doi:

Substances chimiques

Phosphates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

427

Références

Clin Chim Acta. 2016 Oct 1;461:76-82
pubmed: 27475981
J Am Soc Nephrol. 2004 Aug;15(8):2208-18
pubmed: 15284307
Hosp Pract (1995). 2018 Aug;46(3):121-127
pubmed: 29848117
Ren Fail. 2019 Nov;41(1):72-79
pubmed: 30909778
J Intensive Care Med. 2020 May;35(5):485-493
pubmed: 29519205
Arch Intern Med. 2007 May 14;167(9):879-85
pubmed: 17502528
J Nephrol. 2019 Dec;32(6):895-908
pubmed: 31515724
Br J Nutr. 2018 Dec 17;:1-6
pubmed: 30554575
Clin J Am Soc Nephrol. 2010 Dec;5(12):2251-7
pubmed: 20688884
Am J Med. 2013 Apr;126(4):311-8
pubmed: 23375678
J Am Soc Nephrol. 2009 Feb;20(2):397-404
pubmed: 18987306
Medicina (Kaunas). 2020 Mar 02;56(3):
pubmed: 32131462
BMJ Evid Based Med. 2020 Jan 24;:
pubmed: 31980468
Kidney Int. 2008 Jul;74(2):148-57
pubmed: 18449174
Atherosclerosis. 2012 Feb;220(2):310-8
pubmed: 21962238
Semin Dial. 2018 May;31(3):213-218
pubmed: 29405468
Postgrad Med J. 2020 Jan 7;:
pubmed: 31911444
J Am Soc Nephrol. 2009 Jul;20(7):1504-12
pubmed: 19406976
BMC Nephrol. 2016 Jan 09;17:6
pubmed: 26748909
BMC Nephrol. 2019 Feb 4;20(1):37
pubmed: 30717691
Crit Care. 2010;14(4):R147
pubmed: 20682049
Nephrol Dial Transplant. 2007 Oct;22(10):2909-16
pubmed: 17517792
Medicine (Baltimore). 2000 Jan;79(1):1-8
pubmed: 10670405
JAMA. 2009 Feb 11;301(6):629-35
pubmed: 19211470
Clin Nephrol. 2018 Aug;90(2):79-86
pubmed: 29578398
Curr Opin Nephrol Hypertens. 2019 Sep;28(5):441-447
pubmed: 31313675
Hosp Pract (1995). 2019 Apr;47(2):73-79
pubmed: 30633593
Am Heart J. 2008 Sep;156(3):556-63
pubmed: 18760141
Nephrology (Carlton). 2015 Dec;20(12):881-6
pubmed: 26032233
Med Sci Monit. 2019 Jan 24;25:691-699
pubmed: 30674864
PLoS One. 2013;8(3):e58348
pubmed: 23505492
South Med J. 1988 Aug;81(8):1068-9
pubmed: 3406790
Pediatr Nephrol. 2012 Nov;27(11):2039-2048
pubmed: 22552885
Ann Clin Lab Sci. 2006 Winter;36(1):67-72
pubmed: 16501239
J Am Soc Nephrol. 2005 Jun;16(6):1788-93
pubmed: 15814832
J Nephrol. 2018 Apr;31(2):241-247
pubmed: 28975589
J Am Soc Nephrol. 2005 Feb;16(2):520-8
pubmed: 15615819
Nephrology (Carlton). 2020 Jan;25(1):22-28
pubmed: 31081186
Int J Clin Pract. 2020 Apr;74(4):e13461
pubmed: 31830348

Auteurs

Charat Thongprayoon (C)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Wisit Cheungpasitporn (W)

Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Panupong Hansrivijit (P)

Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA, USA.

Sorkko Thirunavukkarasu (S)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Api Chewcharat (A)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Juan Medaura (J)

Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Michael A Mao (MA)

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, 32224, USA.

Kianoush B Kashani (KB)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. kashani.kianoush@mayo.edu.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA. kashani.kianoush@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH